DK2137192T3 - Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme - Google Patents

Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme

Info

Publication number
DK2137192T3
DK2137192T3 DK08735211.8T DK08735211T DK2137192T3 DK 2137192 T3 DK2137192 T3 DK 2137192T3 DK 08735211 T DK08735211 T DK 08735211T DK 2137192 T3 DK2137192 T3 DK 2137192T3
Authority
DK
Denmark
Prior art keywords
galantamine
prodrugs
derivatives
treatment
human brain
Prior art date
Application number
DK08735211.8T
Other languages
Danish (da)
English (en)
Inventor
Alfred Maelicke
Original Assignee
Neurodyn Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2137192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurodyn Life Sciences Inc filed Critical Neurodyn Life Sciences Inc
Application granted granted Critical
Publication of DK2137192T3 publication Critical patent/DK2137192T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK08735211.8T 2008-04-14 2008-04-14 Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme DK2137192T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/002929 WO2009127218A1 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Publications (1)

Publication Number Publication Date
DK2137192T3 true DK2137192T3 (da) 2014-05-26

Family

ID=40019199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08735211.8T DK2137192T3 (da) 2008-04-14 2008-04-14 Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme

Country Status (8)

Country Link
EP (1) EP2137192B8 (enExample)
JP (1) JP5504253B2 (enExample)
CN (1) CN102007129B (enExample)
CA (1) CA2721007C (enExample)
DK (1) DK2137192T3 (enExample)
ES (1) ES2463715T3 (enExample)
PL (1) PL2137192T3 (enExample)
WO (1) WO2009127218A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880399T3 (es) 2012-07-27 2021-11-24 Neurodyn Life Sciences Inc Biodisponibilidad cerebral mejorada de galantamina mediante formulaciones seleccionadas y administración transmucosa de profármacos lipofílicos
CN108245522A (zh) * 2012-07-27 2018-07-06 神经动力生命科学公司 Gln-1062盐在制备治疗与认知障碍相关的脑疾病的药物中的应用
WO2015148487A1 (en) * 2014-03-25 2015-10-01 Synaptec Development Llc Treatment of autism
EP3122187A4 (en) * 2014-03-25 2017-11-15 Emicipi LLC Treatment of rett syndrome
WO2015176069A2 (en) * 2014-05-16 2015-11-19 Synaptec Development Llc CLEARANCE OF AMYLOID ß
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
US12208167B1 (en) 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
JP2755403B2 (ja) 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1282099A (en) * 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
WO2000032199A1 (de) 1998-12-01 2000-06-08 Sanochemia Pharmazeutika Aktiengesellschaft Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden
MXPA02005667A (es) 1999-12-10 2004-09-10 Bonnie Davis Analogos de galantamina y licoramina como moduladores de los receptores nicotinicos.
JP2003529602A (ja) 2000-03-31 2003-10-07 ザノヒェミア・ファルマツォイティカ・アーゲー ガランタミンの新規誘導体および類似体
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
AU2004276354B2 (en) 2003-09-26 2009-07-09 Scinopharm Taiwan, Ltd. Resolution of a narwedine amide derivative
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Also Published As

Publication number Publication date
CA2721007C (en) 2014-04-29
CN102007129B (zh) 2014-05-07
ES2463715T3 (es) 2014-05-29
CN102007129A (zh) 2011-04-06
PL2137192T3 (pl) 2014-07-31
CA2721007A1 (en) 2009-10-22
JP5504253B2 (ja) 2014-05-28
EP2137192B1 (en) 2014-02-19
JP2011516588A (ja) 2011-05-26
EP2137192B8 (en) 2014-06-11
EP2137192A1 (en) 2009-12-30
WO2009127218A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK2381965T3 (da) Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2227257T3 (da) Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
DK2207550T3 (da) Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
BRPI0812755A2 (pt) Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
DK2252317T3 (da) Behandling af makuladegeneration
DK2137192T3 (da) Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
BRPI0917440A2 (pt) composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
DK2148667T3 (da) Anvendelse af cyclohexanhexolderivater til behandling af øjensygdomme
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
PT2623499E (pt) Derivado de 1,2,4-triazolona para tratamento de distúrbios de humor